CKD Receivables

The latest receivables for 6407.T is $51B as of June 2026. That compares with $44B in the prior-year period — up 14.4% year over year. Investors often review this figure alongside CKD's historical trend and sector peers before judging valuation or financial health.

Over the past year, 6407.T's receivables moved from $44B to $51B — a 14.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in CKD's operating scale or balance-sheet position.

A receivables figure of $51B for 6407.T is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 6407.T's receivables ($51B), review year-over-year change from $44B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.